

REVENIO

Revenio Group Corporation: iCare ILLUME, a screening solution using artificial intelligence, has been launched today

Revenio Group Corporation, Press release, April 27, 2022 at 3.00 p.m. (EEST)

iCare ILLUME, a screening solution using artificial intelligence has been launched today

iCare ILLUME, a screening solution using artificial intelligence, has been launched today as part of iCare Solutions.

iCare ILLUME is a unique combination of specialized screening software with artificial intelligence (AI) by our partner Thirona and iCare DRSplus fundus imaging system with TrueColor Confocal capabilities. iCare ILLUME instantly detects signs of vision-threatening diabetic retinopathy with AI. Retina images taken with the iCare DRSplus fundus imaging system are automatically transferred to iCare ILLUME solution cloud service and the report is instantly available. This allows the utilization of the high-quality images generated by the iCare DRSplus fundus imaging system even more extensively as support for clinical decision-making. The iCare ILLUME solution can be used for screening other eye diseases in the future.

iCare Solutions provides digital clinical tools that drive greater efficiency, enhance quality in eye care, and mean that health care professionals can provide care to a greater number of patients. iCare Solutions pairs high-quality fundus imaging systems and tonometers with intuitive, user-friendly, and secure clinical software. Digital tools that connect eye care pathways are the answer to increasing productivity while maintaining a high quality of care.

Revenio Group CEO Jouni Toijala comments: "Diabetes prevalence is increasing fast globally, and the world needs innovative solutions so screening coverage can be increased, and at the same time ophthalmologists can focus on the patients with real signs of eye diseases. Our software solutions are playing an increasingly important role in eye care pathways, and we continue to be the trusted developer for ophthalmic diagnostic devices."

More information on iCare ILLUME can be found at www.icare-world.com/product/icare-illumel/

For further information, please contact

Vice President, Sales & Marketing Tomi Karvo

tel. +358 40 544 9528

tomi.karvo@icare-world.com

Distribution

Principal media

www.revenio.fi

REVENIO

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: iCare ILLUME, a screening solution using artificial intelligence, has been launched today](#)